Roger Susi Sells 2,500 Shares of iRadimed (NASDAQ:IRMD) Stock

Key Points

• CEO Roger Susi sold 2,500 shares at an average price of $100.28 for $250,700, a 0.11% reduction that leaves him with 2,232,500 shares; the transaction was disclosed in an SEC filing.
• iRadimed beat quarterly estimates and raised guidance, reporting $0.54 EPS (vs. $0.49 expected) and $22.69M revenue, setting Q1 2026 guidance of 0.440–0.480 EPS and FY 2026 guidance of 2.060–2.210 EPS, while also increasing its quarterly dividend to $0.20 and carrying a consensus analyst target of $120 ("Moderate Buy").

iRadimed Corporation (NASDAQ:IRMD - Get Free Report) CEO Roger Susi sold 2,500 shares of the business's stock in a transaction that occurred on Tuesday, March 24th. The stock was sold at an average price of $100.28, for a total transaction of $250,700.00. Following the completion of the transaction, the chief executive officer owned 2,232,500 shares of the company's stock, valued at approximately $223,875,100. The trade was a 0.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

iRadimed Trading Up 0.8%

IRMD traded up $0.81 during trading on Wednesday, hitting $101.78. 52,623 shares of the company's stock traded hands, compared to its average volume of 74,394. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of 58.16 and a beta of 1.12. The company's 50 day simple moving average is $100.53 and its two-hundred day simple moving average is $90.14. iRadimed Corporation has a 12-month low of $47.48 and a 12-month high of $107.90.

iRadimed (NASDAQ:IRMD - Get Free Report) last posted its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.05. The firm had revenue of $22.69 million during the quarter, compared to analysts' expectations of $21.60 million. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. On average, equities analysts expect that iRadimed Corporation will post 1.66 EPS for the current year.

iRadimed Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 6th. Shareholders of record on Monday, February 23rd were paid a dividend of $0.20 per share. The ex-dividend date was Monday, February 23rd. This represents a $0.80 annualized dividend and a yield of 0.8%. This is an increase from iRadimed's previous quarterly dividend of $0.17. iRadimed's dividend payout ratio (DPR) is currently 45.71%.

Institutional Investors Weigh In On iRadimed

A number of large investors have recently made changes to their positions in IRMD. T. Rowe Price Investment Management Inc. grew its stake in shares of iRadimed by 410.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider's stock valued at $24,893,000 after purchasing an additional 205,783 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of iRadimed by 37.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 205,227 shares of the medical equipment provider's stock worth $19,964,000 after purchasing an additional 55,426 shares during the period. Informed Momentum Co LLC purchased a new position in shares of iRadimed in the fourth quarter worth approximately $5,361,000. SG Americas Securities LLC boosted its holdings in shares of iRadimed by 88.6% in the fourth quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider's stock worth $6,848,000 after buying an additional 33,072 shares during the last quarter. Finally, Invesco Ltd. grew its position in iRadimed by 473.9% during the fourth quarter. Invesco Ltd. now owns 35,131 shares of the medical equipment provider's stock valued at $3,418,000 after buying an additional 29,010 shares during the period. 92.34% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

IRMD has been the subject of a number of research analyst reports. Lake Street Capital reiterated a "buy" rating and issued a $120.00 price target on shares of iRadimed in a research note on Wednesday, February 11th. Roth Mkm restated a "buy" rating and set a $120.00 price objective on shares of iRadimed in a research report on Tuesday, February 10th. Finally, Weiss Ratings restated a "buy (b-)" rating on shares of iRadimed in a report on Monday, December 29th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, iRadimed currently has a consensus rating of "Moderate Buy" and an average target price of $120.00.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.